SIOUX FALLS, S.D., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Eddie J. Sullivan, Ph.D., co-founder, President and Chief Executive Officer of SAB Biotherapeutics will present at the 35th Annual Piper Sandler Healthcare Conference, taking place from November 28 to November 30, 2023 at The Lotte New York Palace in New York.
The conference is an invitation only event that brings together key industry executives, investors and other professionals to provide multiple perspectives, investigate critical trends and identify leaders in the healthcare space.
Dr. Sullivan's presentation will take place on Wednesday, November 29, at 1:30 pm ET in Staten Island Track, Kennedy 1, 4th Floor.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics (SAB) is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The company's lead asset, SAB-142, targets ...